R3 VASCULAR INC.
R3 Vascular is a privately held medical device company developing new therapies for the treatment of peripheral artery disease.
R3 VASCULAR INC.
Website Url:
http://www.r3vascular.com
Status:
Active
Total Funding:
17.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Content Delivery Network Microsoft Azure DNS YouTube Typekit Network Solutions DNS Squarespace
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Kamal Ramzipoor President and CEO @ R3 Vascular Inc.
President and CEO
2020-11-01
Investors List
415 CAPITAL
415 CAPITAL investment in Series A - R3 Vascular Inc.
Official Site Inspections
http://www.r3vascular.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "R3 Vascular Inc."
About — R3 Vascular
Afsoon Fallahi, Ph.D. Director of Operations and Polymer Engineering, Formulations and Analytical Chemistry/API Afsoon is a polymer and biomaterial scientist/engineer with …See details»
R3 Vascular - Crunchbase Company Profile & Funding
R3 Vascular creates bioresorbable scaffold technology with a sirolimus coating for the treatment of peripheral arterial disease. R3 Vascular's polymer and …See details»
R3 Vascular Inc. - LinkedIn
R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus ...See details»
R3 Vascular, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Mar 7, 2025 R3 Vascular is headquartered in Mountain View, California. More information can be found at www.r3vascular.com. Media Contact:David Gutierrez, Dresner Corporate …See details»
Press — R3 Vascular
Nov 4, 2024 R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO. MOUNTAIN VIEW, CA – May 9, 2024 – R3 Vascular Inc., a medical device company dedicated to …See details»
R3 Vascular - 415 Capital
R3 has developed a novel technology platform of fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of Peripheral Artery Disease (PAD).See details»
R3 Vascular
R3 Vascular is developing a world-class Bioresorbable scaffold technology with a sirolimus coating for the treatment of peripheral arterial disease.See details»
R3 Vascular Inc Announces $87 Million in Series B Financing and ...
MOUNTAIN VIEW, Calif. – May 9, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral …See details»
R3 Vascular Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for R3 Vascular Inc. of Mountain View, CA. Get the latest business insights from Dun & Bradstreet.See details»
R3 Vascular Inc. - The Org
R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a …See details»
R3 Vascular - VentureRadar
"R3 Vascular is a privately held, early-stage medical device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds …See details»
R3 Vascular - PitchBook
R3 Vascular General Information Description. Developer and manufacturer of medical device metallic stents designed to treat peripheral arterial diseases. The company offers …See details»
Bioresorbable scaffold maker R3 Vascular raises $87M - MassDevice
May 9, 2024 R3 Vascular announced today that it closed an $87 million Series B financing round and appointed Christopher Owens as president and CEO.See details»
R3 Vascular - Products, Competitors, Financials, Employees ...
R3vascular.com. Overview & Products; Financials; People; Alternatives & Competitors; Founded Year 2019. Stage Series B | Alive. Total Raised $104.8M. Last Raised $87M | 1 yr ago. About …See details»
R3 Vascular secures funding to support bioresorbable scaffold trial
May 10, 2024 Owens’ experience includes leadership roles at Gynesonics, IDEV Technologies, MicroVention, and Bausch & Lomb’s Surgical Division. Owens said: “R3 Vascular’s novel …See details»
R3 Vascular | VentureRadar
Website: https://www.r3vascular.com/ Develops novel bioresorbable vascular scaffolds to deliver stent-like support and anti-inflammatory results, with a primary ...See details»
R3 Vascular Announces $87 Million in Series B Financing and
May 9, 2024 More information can be found at www.r3vascular.com. About Deerfield Management Deerfield is an investment management firm committed to advancing healthcare …See details»
R3 Vascular Announces $87 Million in Series B ... - Markets Insider
May 9, 2024 More information can be found at www.r3vascular.com. About Deerfield Management Deerfield is an investment management firm committed to advancing healthcare …See details»
R3 Vascular Secures WCG IRB Approval and CMS Category B …
Jan 13, 2025 More information can be found at www.r3vascular.com. Media Contact: David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com.See details»
R3 Vascular Announces First Patient Treated in ELITE-BTK
23 hours ago MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class …See details»